22Rv1 Xenograft Model Service for Prostate Cancer

The 22Rv1 cell line provides a robust and clinically relevant in vivo platform for investigating androgen receptor (AR) signaling and therapeutic resistance in prostate cancer. As a specialized pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision 22Rv1 Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your prostate cancer drug discovery and development pipeline.

Overview of 22Rv1 Xenograft Model for Prostate Cancer

The 22Rv1 xenograft model is an essential in vivo translational system utilized in oncology research for studying castration-resistant prostate cancer (CRPC). By transplanting human 22Rv1 cells into immunodeficient rodent hosts, this model effectively reproduces the solid tumor growth characteristics, histopathological architecture, and castration-resistant proliferative patterns typical of advanced human prostate malignancies.

Biologically, the 22Rv1 model is highly valued for its expression of both full-length androgen receptors and constitutively active AR splice variants (such as AR-V7). This unique molecular profile makes it an ideal system for evaluating the efficacy of next-generation AR inhibitors and novel therapies targeting androgen-independent growth. The model maintains critical phenotypic features of human prostate cancer, demonstrating robust tumor formation and responsiveness to diverse pharmacological agents in an in vivo environment. Consequently, the 22Rv1 model is extensively deployed in pre-clinical screening programs to assess the anti-tumor potency of novel therapeutic candidates.

Fig 1. Western blot analysis of RNF19A and circRNF19A-490aa in 22Rv1 and LNCaP cells with circRNF19A overexpression or knockdown. (Li J, et al., 2024)

Cell Line Information: 22Rv1

The 22Rv1 cell line is derived from a human prostate carcinoma xenograft, serially propagated in mice after castration-induced regression and relapse. These cells exhibit stable growth characteristics in vitro and retain key characteristics of androgen-independent prostate cancer, making them a reliable choice for pre-clinical model development.

Our Services

Workflow of 22Rv1 Xenograft Model Construction

• Cell Culture & Quality Control: Human 22Rv1 cells are expanded in vitro using certified nutrient media under optimized physiological conditions. STR authentication and mycoplasma screening are performed prior to inoculation to ensure absolute genetic integrity and purity.
• Host Selection & Preparation: Immunodeficient rodent models are utilized for tumor engraftment, with all animals maintained in a controlled, pathogen-free environment to ensure physiological stability and consistency throughout the study.
• Precision Inoculation: A calibrated suspension of high-viability 22Rv1 cells is prepared, often supplemented with an extracellular matrix (e.g., Matrigel) to optimize take efficiency. Cells are inoculated in vivo via subcutaneous injection into the host flank to facilitate the development of a measurable, solid tumor.
• Longitudinal Monitoring: Tumor size is measured systematically using digital calipers to monitor volume progression. Animal health, activity, and body weight are recorded periodically to document systemic tolerance and clinical status.
• Randomization & Treatment: Once solid tumors reach a predefined, statistically significant volume, animals are randomized into matched cohorts to ensure baseline parity before the initiation of customized therapeutic dosing regimens.

Fig 2. 22Rv1 Xenograft Model Construction Workflow

Case Study - 22Rv1 Xenograft Model Development

A pre-clinical validation study was conducted using the 22Rv1 xenograft model to evaluate the therapeutic efficacy of a novel androgen receptor antagonist. Following the successful subcutaneous inoculation of 22Rv1 cells into immunodeficient mice, the host animals developed firm, rapidly growing solid tumors. The treatment group demonstrated a clear, statistically significant inhibition of tumor growth compared to the vehicle-treated control group, confirming the model's sensitivity and reliability for screening novel therapeutic interventions in a castration-resistant setting.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing specialized prostate cancer lineages, providing highly reproducible in vivo translational platforms for complex hormonal-resistance research.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready report providing comprehensive tumor growth metrics and statistical validations.

Contact us

Accelerating your prostate cancer drug pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our 22Rv1 platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.